SA
VRTX icon

Shilanski & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Shilanski & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,983
Closed -$812K – 104
2020
Q3 		$812K Buy
+2,983
New +$823K 0.55% 54

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Shilanski & Associates's VRTX Position: Q4 2020 in Review

Shilanski & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 2,983 shares — an estimated $812K sold.

Shilanski & Associates first reported a position in VRTX in Q3 2020 and held it in 1 quarter. The position peaked at $812K in Q3 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Shilanski & Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Shilanski & Associates sold 2,983 Vertex Pharmaceuticals shares in Q4 2020, an estimated $812K.
  • Shilanski & Associates first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Shilanski & Associates's Vertex Pharmaceuticals position peaked at $812K in Q3 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Shilanski & Associates's 13F filing for Q4 2020, filed 3 Feb 2021.